Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a report released on Saturday.

ALNY has been the subject of a number of other research reports. BMO Capital Markets reissued an outperform rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Citigroup dropped their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating for the company in a report on Friday, February 16th. Chardan Capital dropped their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a buy rating for the company in a report on Friday, February 16th. Wolfe Research began coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. They issued a peer perform rating for the company. Finally, The Goldman Sachs Group lowered shares of Alnylam Pharmaceuticals from a buy rating to a neutral rating and dropped their price objective for the company from $230.00 to $173.00 in a report on Friday, February 16th. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of Moderate Buy and an average target price of $216.12.

Alnylam Pharmaceuticals Stock Down 0.7 %

ALNY opened at $146.72 on Friday. Alnylam Pharmaceuticals has a twelve month low of $143.52 and a twelve month high of $218.88. The company has a 50-day simple moving average of $153.02 and a 200 day simple moving average of $167.34. The stock has a market capitalization of $18.48 billion, a price-to-earnings ratio of -41.21 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company posted ($1.68) EPS. Sell-side analysts anticipate that Alnylam Pharmaceuticals will post -4.54 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Quent Capital LLC grew its position in Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the period. KB Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at $35,000. Anchor Investment Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $38,000. Robeco Institutional Asset Management B.V. grew its position in Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the period. Finally, GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.